Abstract
Gp130 cytokines are involved in the regulation of numerous biological processes, including hematopoiesis, immune response, inflammation, cardiovascular action, and neuronal survival. These cytokines share glycoprotein 130 as a common signal transducer in their receptor complex and typically activate STAT3. Most gp130 cytokines have paracrine or endocrine actions, and their levels can be measured in circulation in rodents and humans. In recent years, various laboratories have conducted studies to demonstrate that gp130 cytokines can modulate adipocyte development and function. Therefore, these studies suggest that some gp130 cytokines may be viable anti-obesity therapeutics. In this review, we will summarize the reported effects of gp130 cytokines on adipocyte differentiation and adipocyte function. In addition, the modulation of gp130 cytokines in conditions of obesity, insulin resistance, and Type 2 diabetes will be presented.
Current Pharmaceutical Design
Title: The gp130 Receptor Cytokine Family: Regulators of Adipocyte Development and Function
Volume: 17 Issue: 4
Author(s): Ursula A. White and Jacqueline M. Stephens
Affiliation:
Keywords: Adipocyte, gp130, STAT3, IL-6, OSM, LIF, CT-1
Abstract: Gp130 cytokines are involved in the regulation of numerous biological processes, including hematopoiesis, immune response, inflammation, cardiovascular action, and neuronal survival. These cytokines share glycoprotein 130 as a common signal transducer in their receptor complex and typically activate STAT3. Most gp130 cytokines have paracrine or endocrine actions, and their levels can be measured in circulation in rodents and humans. In recent years, various laboratories have conducted studies to demonstrate that gp130 cytokines can modulate adipocyte development and function. Therefore, these studies suggest that some gp130 cytokines may be viable anti-obesity therapeutics. In this review, we will summarize the reported effects of gp130 cytokines on adipocyte differentiation and adipocyte function. In addition, the modulation of gp130 cytokines in conditions of obesity, insulin resistance, and Type 2 diabetes will be presented.
Export Options
About this article
Cite this article as:
A. White Ursula and M. Stephens Jacqueline, The gp130 Receptor Cytokine Family: Regulators of Adipocyte Development and Function, Current Pharmaceutical Design 2011; 17 (4) . https://dx.doi.org/10.2174/138161211795164202
| DOI https://dx.doi.org/10.2174/138161211795164202 |
Print ISSN 1381-6128 |
| Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Multidisciplinary Pharmaceutical Drug Design Strategies in the Progress of Drug Discovery"
The process of developing a drug is time and money-consuming, but also fascinating. The development of numerous computational techniques, synthetic methodologies, formulation-based drug discovery, etc., has improved the drug discovery process. The process of developing new drugs is significantly hampered by drug-poor pharmacodynamics and pharmacokinetic problems. To address these challenges, ...read more
Accelerating Cancer drug discovery using Artificial intelligence and In Silico methods
The Artificial intelligence and in silico methods speed up cancer drug discovery, transforming how new treatments are developed. Artificial intelligence, along with in silico methods, allows for quick investigation of large biological datasets, helping identify potential drug targets with remarkable speed and accuracy. Machine learning models help us understand how ...read more
Advances in the Molecular Pathogenesis of Inflammatory Bowel Disease.
This thematic issue will emphasize the recent breakthroughs in the mechanisms of Inflammatory bowel disease (IBD) pathogenesis and devotes some understanding of both Crohn’s and ulcerative colitis. It is expected to include studies about cellular and genetic aspects, which help to precipitate the disease, and the immune system-gut microbiome relations ...read more
Artificial Intelligence and Computational Approaches in Drug Discovery
Computer-aided drug design (CADD) and artificial intelligence (AI) are fundamentally reshaping drug discovery pipelines by significantly enhancing efficiency in molecular screening, rational drug design, and natural product development. In the field of molecular screening, the integration of virtual high-throughput screening with advanced AI models enables rapid analysis of million-compound libraries, ...read more
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Long Noncoding RNA OIP5-AS1 Overexpression Promotes Viability and Inhibits High Glucose-Induced Oxidative Stress of Cardiomyocytes by Targeting MicroRNA-34a/SIRT1 Axis in Diabetic Cardiomyopathy
Endocrine, Metabolic & Immune Disorders - Drug Targets Green Tea Catechins and Cardiovascular Health: An Update
Current Medicinal Chemistry Clinical Implications of Recent Insights into the Structural Biology of Beta2 Adrenoceptors
Current Drug Targets Mesenchymal Stem Cell Therapy for Acetaminophen-related Liver Injury: A Systematic Review and Meta-analysis of Experimental Studies <i>In Vivo</i>
Current Stem Cell Research & Therapy Bridging Innate Immunity and Myocardial Ischemia/Reperfusion Injury: The Search for Therapeutic Targets
Current Pharmaceutical Design Left Ventricular Hypertrophy in Isolated Aortic Stenosis: Primetime for the Ventricle
Current Pharmaceutical Biotechnology Pharmacological Therapy of Pericardial Diseases
Current Pharmaceutical Design Kinin Receptors in Vascular Biology and Pathology
Current Vascular Pharmacology Risk Profiles in Type 2 Diabetes (Metabolic Syndrome): Integration of IL-10 Polymorphisms and Laboratory Parameters to Identify Vascular Damages Related Complications
Current Pharmaceutical Design Review on the Clinical Pharmacology of Hydroxychloroquine Sulfate for the Treatment of COVID-19
Current Drug Metabolism Hepatic and Systemic Inflammation for Left Ventricular Mass in Physically Fit Adults: CHIEF Heart Study
Endocrine, Metabolic & Immune Disorders - Drug Targets COVID-19 Invades Several Important Organs other than the Lungs: Organs Crosstalk
Coronaviruses Current Landscape of Gene Therapy for the Treatment of Cardiovascular Disorders
Current Gene Therapy Vascular and Cardiac Oxidative Stress and Inflammation as Targets for Cardioprotection
Current Pharmaceutical Design Pharmacogenomic Considerations in the Treatment of the Pediatric Cardiomyopathy Called Barth Syndrome
Recent Patents on Biotechnology Targeted Cancer Therapy: The Next Generation of Cancer Treatment
Current Drug Discovery Technologies Metabolic Ataxias in Adults
Current Molecular Medicine Erythropoietin and mTOR: A “One-Two Punch” for Aging-Related Disorders Accompanied by Enhanced Life Expectancy
Current Neurovascular Research A Comparative Summary on Antioxidant-like Actions of Timolol with Other Antioxidants in Diabetic Cardiomyopathy
Current Drug Delivery Natural and Synthetic Naphthoquinones Active Against Trypanosoma Cruzi: An Initial Step Towards New Drugs for Chagas Disease
Current Medicinal Chemistry





